BR112014001083A8 - composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto - Google Patents

composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto

Info

Publication number
BR112014001083A8
BR112014001083A8 BR112014001083A BR112014001083A BR112014001083A8 BR 112014001083 A8 BR112014001083 A8 BR 112014001083A8 BR 112014001083 A BR112014001083 A BR 112014001083A BR 112014001083 A BR112014001083 A BR 112014001083A BR 112014001083 A8 BR112014001083 A8 BR 112014001083A8
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
treating diseases
formula
Prior art date
Application number
BR112014001083A
Other languages
English (en)
Other versions
BR112014001083A2 (pt
BR112014001083B1 (pt
BR112014001083B8 (pt
Inventor
Rasheed Mohammed Abdul
Karbhari Shinde Anil
Bhyrapuneni Gopinadh
Ravula Jyothsna
Jayarajan Pradeep
Kumar Roayapalley Praveen
Nirogi Ramakrishna
Kambhampati Ramasastri
Rao Ravella Srinivasa
Murthy Patnala Sriramachandra
Yarlagadda Suresh
Jasti Venkateswarlu
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BR112014001083A2 publication Critical patent/BR112014001083A2/pt
Publication of BR112014001083A8 publication Critical patent/BR112014001083A8/pt
Publication of BR112014001083B1 publication Critical patent/BR112014001083B1/pt
Publication of BR112014001083B8 publication Critical patent/BR112014001083B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

composto, processo para a preparação de um composto e composição farmacêutica. a presente invenção se refere a novos compostos tendo a fórmula (i), e aos seus sais farmaceuticamente aceitáveis e composições contendo os mesmos. a presente invenção também se refere a um processo para a preparação dos referidos novos compostos acima, e dos seus sais farmaceuticamente aceitáveis. os compostos de fórmula (i) são úteis no tratamento de várias desordens que são relacionadas aos receptores de 5-ht4.
BR112014001083A 2011-09-19 2012-01-05 Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto BR112014001083B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3203CH2011 2011-09-19
IN3203/CHE/2011 2011-09-19
PCT/IN2012/000011 WO2013042135A1 (en) 2011-09-19 2012-01-05 Heteroaryl compounds as 5-ht4 receptor ligands

Publications (4)

Publication Number Publication Date
BR112014001083A2 BR112014001083A2 (pt) 2019-10-01
BR112014001083A8 true BR112014001083A8 (pt) 2021-08-24
BR112014001083B1 BR112014001083B1 (pt) 2022-02-01
BR112014001083B8 BR112014001083B8 (pt) 2022-06-14

Family

ID=46001349

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014001083A BR112014001083B8 (pt) 2011-09-19 2012-01-05 Composto, processo para a preparação de um composto, composição farmacêutica, uso da composiçâo farmacêutica e uso do composto

Country Status (26)

Country Link
US (2) US9079894B2 (pt)
EP (1) EP2758394B1 (pt)
JP (1) JP5714729B2 (pt)
KR (1) KR101551481B1 (pt)
CN (1) CN103380131B (pt)
AP (1) AP3307A (pt)
AU (1) AU2012311057B2 (pt)
BR (1) BR112014001083B8 (pt)
CA (1) CA2823548C (pt)
CY (1) CY1116173T1 (pt)
DK (1) DK2758394T3 (pt)
EA (1) EA022374B1 (pt)
ES (1) ES2531885T3 (pt)
HK (1) HK1187340A1 (pt)
HR (1) HRP20150229T1 (pt)
IL (1) IL231305A0 (pt)
ME (1) ME02107B (pt)
MX (1) MX337721B (pt)
PL (1) PL2758394T3 (pt)
PT (1) PT2758394E (pt)
RS (1) RS53940B1 (pt)
SG (1) SG2014003560A (pt)
SI (1) SI2758394T1 (pt)
SM (1) SMT201500087B (pt)
WO (1) WO2013042135A1 (pt)
ZA (1) ZA201309100B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012267797A1 (en) * 2011-06-07 2014-01-09 Sumitomo Dainippon Pharma Co., Ltd. Indazole- and pyrrolopyridine-derivative and pharmaceutical use thereof
CN105120851A (zh) * 2013-04-05 2015-12-02 Abc生物科学公司 用于医疗用途，具体为用于治疗与氧化应激相关的疾病或者炎症和用于保存或者洗涤器官的barettin及其衍生物
CA2932428C (en) 2013-12-16 2017-10-24 Suven Life Sciences Limited Indazole compounds as 5-ht4 receptor agonists
PL3180333T3 (pl) 2014-08-16 2020-12-28 Suven Life Sciences Limited Proces przygotowania na dużą skalę szczawianu 1-izopropylo-3-{5- [1-(3-metoksypropylo) piperydyn-4-ylo]-[1,3,4]oksadiazol-2-ilo}-1h-indazolu
PL3265459T3 (pl) * 2015-02-13 2019-09-30 Suven Life Sciences Limited Związki amidowe jako agoniści receptora 5-HT4
CN107540568A (zh) * 2017-08-25 2018-01-05 许昌恒生制药有限公司 一种乙氧酰胺苯甲酯的制备方法
JP2022505388A (ja) * 2018-10-18 2022-01-14 スヴェン・ライフ・サイエンシーズ・リミテッド ５－ｈｔ４受容体アゴニストの新しい使用
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN110746450A (zh) * 2019-09-17 2020-02-04 济南康和医药科技有限公司 一种贝前列素钠关键中间体的合成方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596933A1 (en) * 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-ht4 receptor antagonists
TW360653B (en) * 1995-03-01 1999-06-11 Janssen Pharmaceutica Nv A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition
BR9611311A (pt) 1995-11-09 1999-06-29 Synthelabo Derivados de 5-fenil-3-(piperidin-4-il)-1,3,4-oxadiazol-2(3h)-ona úteis como ligantes dos receptores 5-ht4 ou h3
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
WO2005049608A1 (en) 2003-11-24 2005-06-02 Pfizer Japan, Inc. Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
EP1856110B1 (en) 2005-02-22 2011-06-22 Pfizer Inc. Oxyindole derivatives as 5ht4 receptor agonists
US8816090B2 (en) 2005-02-25 2014-08-26 Pfizer Inc. Benzisoxazole derivatives
ES2333545T3 (es) 2005-07-22 2010-02-23 Pfizer, Inc. Derivados de indazolcarboxamida como agonistas de receptores 5ht4.
ES2397401T3 (es) * 2005-12-23 2013-03-06 F. Hoffmann-La Roche Ag Derivados de aril-isoxazol-4-il-oxadiazol
US20080167286A1 (en) * 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US20080255203A1 (en) * 2007-04-12 2008-10-16 Abbott Laboratories Heterocyclic compounds and their methods of use
JP5656880B2 (ja) * 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール

Also Published As

Publication number Publication date
EA022374B1 (ru) 2015-12-30
SI2758394T1 (sl) 2015-05-29
EP2758394B1 (en) 2015-02-18
WO2013042135A1 (en) 2013-03-28
CA2823548C (en) 2015-10-27
EA201391056A1 (ru) 2013-12-30
KR20130109228A (ko) 2013-10-07
CN103380131B (zh) 2015-12-02
MX2013014577A (es) 2014-03-31
AP3307A (en) 2015-06-30
US20150283125A1 (en) 2015-10-08
ME02107B (me) 2015-10-20
MX337721B (es) 2016-03-16
AP2013007301A0 (en) 2013-12-31
US9636335B2 (en) 2017-05-02
HK1187340A1 (zh) 2014-04-04
KR101551481B1 (ko) 2015-09-08
PL2758394T3 (pl) 2015-08-31
CY1116173T1 (el) 2017-02-08
CN103380131A (zh) 2013-10-30
AU2012311057B2 (en) 2015-09-17
NZ619776A (en) 2015-04-24
JP5714729B2 (ja) 2015-05-07
DK2758394T3 (en) 2015-04-20
BR112014001083A2 (pt) 2019-10-01
HRP20150229T1 (hr) 2015-04-10
BR112014001083B1 (pt) 2022-02-01
EP2758394A1 (en) 2014-07-30
WO2013042135A8 (en) 2013-08-15
US20140187581A1 (en) 2014-07-03
SMT201500087B (it) 2015-05-05
ZA201309100B (en) 2014-08-27
AU2012311057A1 (en) 2013-08-01
RS53940B1 (en) 2015-08-31
BR112014001083B8 (pt) 2022-06-14
IL231305A0 (en) 2014-04-30
JP2014509320A (ja) 2014-04-17
PT2758394E (pt) 2015-04-22
ES2531885T3 (es) 2015-03-20
SG2014003560A (en) 2014-11-27
US9079894B2 (en) 2015-07-14
CA2823548A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
BR112014001083A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica, método para o tratamento de doenças e uso de um composto
BR112015014222A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de anemia e composição farmacêutica
BR112015012425A2 (pt) composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto
BR112014010576B8 (pt) compostos inibidores de neprilisina (nep), seus usos, processo de preparação dos compostos e composição farmacêutica compreendendo os compostos
BR112013021537A2 (pt) derivados de tiazolilpenil-benzenosulfonamido como inibidores da quinase
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
BR112016016844A2 (pt) Compostos heterocíclicos
BR112012022125A2 (pt) composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
BR112014018959A8 (pt) Compostos, composições farmacêuticas, utilizações de um composto e métodos para o tratamento do câncer
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
BR112015008037A2 (pt) compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
BR112016028876A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos.
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
BR112014010401A8 (pt) Inibidores do vírus da hepatite c rod-like que contêm o fragmento {2-[4-(bifenil-4-il)-1h-imidazo-2-il] pirrolidina-1-carbonilmetil}amina
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/01/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 4A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2679 DE 10/05/2022 POR TER SIDO INDEVIDA.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2665 DE 01/02/2022 QUANTO AO ENDERECO.